{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:15:13Z","timestamp":1794017713885,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["1R61AI149642-01"],"award-info":[{"award-number":["1R61AI149642-01"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/S028919\/1"],"award-info":[{"award-number":["EP\/S028919\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Whilst significant progress has been made to defeat HIV infection, the efficacy of antiretroviral (ARV) therapy in the paediatric population is often hindered by poor adherence. Currently, two long-acting (LA) intramuscular injectable nanosuspensions of rilpivirine (RPV) and cabotegravir (CAB) are in clinical development for paediatric populations. However, administration requires access to healthcare resources, is painful, and can result in needle-stick injuries to the end user. To overcome these barriers, this proof-of-concept study was developed to evaluate the intradermal delivery of RPV LA and CAB LA via self-disabling dissolving microarray patches (MAPs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Dissolving MAPs of two conformations, a conventional pyramidal and a bilayer design, were formulated, with various nanosuspensions of RPV and CAB incorporated within the respective MAP matrix. MAPs were mechanically robust and were capable of penetrating <jats:italic>ex vivo<\/jats:italic> skin with intradermal ARV deposition.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In a single-dose <jats:italic>in vivo<\/jats:italic> study in rats, all ARV MAPs demonstrated sustained release profiles, with therapeutically relevant plasma concentrations of RPV and CAB detected to at least 63 and 28 d, respectively. In a multi-dose <jats:italic>in vivo<\/jats:italic> study, repeated MAP applications at 14-d intervals maintained therapeutically relevant plasma concentrations throughout the duration of the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results illustrate the potential of the platform to repeatedly maintain plasma concentrations for RPV and CAB. As such, these MAPs could represent a viable option to improve adherence in the paediatric population, one that is capable of being painlessly administered in the comfort of the patient\u2019s own home on a biweekly or less frequent basis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s11095-022-03408-6","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T21:02:50Z","timestamp":1665608570000},"page":"1673-1696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy"],"prefix":"10.1007","volume":"40","author":[{"given":"Kurtis","family":"Moffatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismaiel A.","family":"Tekko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitkumar","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Volpe-Zanutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R. J.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mistilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Jarrahian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Akhavein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen O.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0766-4147","authenticated-orcid":false,"given":"Ryan F.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"3408_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081355","volume":"8","author":"H Samji","year":"2013","unstructured":"Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8: e81355.","journal-title":"PLoS ONE"},{"key":"3408_CR2","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587\u201399.","journal-title":"N Engl J Med"},{"key":"3408_CR3","unstructured":"UNAIDS. Global HIV & AIDS statistics - Fact sheet (2021). https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 20 Jan 2022."},{"key":"3408_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1001156","volume":"9","author":"AL Ciaranello","year":"2012","unstructured":"Ciaranello AL, Perez F, Keatinge J, Park J-E, Engelsmann B, Maruva M, et al. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. PLOS Med. 2012;9:1\u201315.","journal-title":"PLOS Med"},{"key":"3408_CR5","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/QAD.0b013e328354bed6","volume":"26","author":"BL Genberg","year":"2012","unstructured":"Genberg BL, Wilson IB, Bangsberg DR, Arnsten J, Goggin K, Remien RH, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26:1415\u201323.","journal-title":"AIDS"},{"key":"3408_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","volume":"15","author":"D Bangsberg","year":"2001","unstructured":"Bangsberg D, Perry S, Charlebois E, Clark R, Robertson M, Zolopa A, Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181\u20133.","journal-title":"AIDS"},{"key":"3408_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/QAI.0b013e31819675e9","volume":"50","author":"VD Lima","year":"2009","unstructured":"Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner JSG. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50:529\u201336.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3408_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077691","author":"V von Wyl","year":"2013","unstructured":"von Wyl V, Klimkait T, Yerly S, Nicca D, Furrer H, Cavassini M, et al. Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV cohort study. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0077691.","journal-title":"PLoS ONE"},{"key":"3408_CR9","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1021\/jm040840e","volume":"48","author":"PAJ Janssen","year":"2005","unstructured":"Janssen PAJ, Lewi PJ, Arnold E, Daeyaert F, De Jonge M, Heeres J, et al. In search of a novel anti-HIV Drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem. 2005;48:1901\u20139.","journal-title":"J Med Chem"},{"key":"3408_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/COH.0000000000000168","volume":"10","author":"C Trezza","year":"2015","unstructured":"Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10:239\u201345.","journal-title":"Curr Opin HIV AIDS"},{"key":"3408_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/jac\/dks404","volume":"68","author":"M Sharma","year":"2013","unstructured":"Sharma M, Saravolatz LD. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother. 2013;68:250\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"3408_CR12","unstructured":"ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living with HIV who are 12 years of Age or Older and Weigh at Least 35 kg. (2022). https:\/\/viivhealthcare.com\/en-us\/media-center\/news\/press-releases\/2022\/march\/viiv-healthcare-announces-us-fda-approval-of-cabenuva\/. Accessed 28 Apr 2022"},{"key":"3408_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/QAI.0000000000000365","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen W, Williams P, Margolis D, Ford SL, Crauwels H, Lou Y, Gould E, Stevens M, Piscitelli S. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. JAIDS J Acquir Immune Defic Syndr. 2014;67:487\u201392.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"3408_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen W, Ford SL, Chen S, Wilfret D, Margolis D, Gould E, Piscitelli S. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. JAIDS J Acquir Immune Defic Syndr. 2014;67:481\u20136.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"3408_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4103\/2141-9248.177973","volume":"5","author":"A Isara","year":"2015","unstructured":"Isara A, Oguzie K, Okpogoro O. Prevalence of needlestick injuries among healthcare workers in the accident and emergency department of a teaching hospital in Nigeria. Ann Med Health Sci Res. 2015;5:392.","journal-title":"Ann Med Health Sci Res"},{"key":"3408_CR16","first-page":"47","volume":"31","author":"AR Isara","year":"2012","unstructured":"Isara AR, Ofili AN. Prevalence of occupational accidents\/injuries among health care workers in a federal medical centre in Southern Nigeria. West Afr J Med. 2012;31:47\u201351.","journal-title":"West Afr J Med"},{"key":"3408_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3126\/ijosh.v3i1.6635","volume":"3","author":"AO Olaleye","year":"2013","unstructured":"Olaleye AO, Ogundele OA, Awokola BI, Olatunya OS, Olaleye OA, Adeyanju T, Omisore AG. Occupational exposure to HIV and use of post-exposure prophylaxis in a general hospital in north Central, Nigeria. Int J Occup Saf Heal. 2013;3:11\u20137.","journal-title":"Int J Occup Saf Heal"},{"key":"3408_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/0974-2727.187917","volume":"9","author":"V Goel","year":"2017","unstructured":"Goel V, Kumar D, Lingaiah R, Singh S. Occurrence of needlestick and injuries among health-care workers of a tertiary care teaching hospital in North India. J Lab Physicians. 2017;9:20\u20135.","journal-title":"J Lab Physicians"},{"key":"3408_CR19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/COH.0000000000000474","volume":"13","author":"F Ferretti","year":"2018","unstructured":"Ferretti F, Boffito M. Rilpivirine long-acting for the prevention and treatment of HIV infection. Curr Opin HIV AIDS. 2018;13:300\u20137.","journal-title":"Curr Opin HIV AIDS"},{"key":"3408_CR20","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.drudis.2017.10.013","volume":"23","author":"RF Donnelly","year":"2018","unstructured":"Donnelly RF, Larra\u00f1eta E. Microarray patches: potentially useful delivery systems for long-acting nanosuspensions. Drug Discov Today. 2018;23:1026\u201333.","journal-title":"Drug Discov Today"},{"key":"3408_CR21","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s11095-014-1301-y","volume":"31","author":"RF Donnelly","year":"2014","unstructured":"Donnelly RF, Moffatt K, Alkilani AZ, Vicente-P\u00e9rez EM, Barry J, McCrudden MTC, Woolfson DA. Hydrogel-forming microneedle arrays can be effectively inserted in skin by self-application: a pilot study centred on pharmacist intervention and a patient information leaflet. Pharm Res. 2014;31:1989\u201399.","journal-title":"Pharm Res"},{"key":"3408_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijpharm.2017.02.011","volume":"521","author":"A Ripolin","year":"2017","unstructured":"Ripolin A, Quinn J, Larraneta E, Vicente-Perez EM, Barry J, Donnelly RF. Successful application of large microneedle patches by human volunteers. Int J Pharm. 2017;521:92\u2013101.","journal-title":"Int J Pharm"},{"key":"3408_CR23","doi-asserted-by":"crossref","unstructured":"Donnelly RF (2018). Clinical translation and industrial development of microneedle-based products. In: Donnelly RF, Singh TRR (eds) Microneedles drug vaccine Deliv. Patient Monit., 1st ed. John Wiley and Sons, Chichester, pp 307\u2013322.","DOI":"10.1002\/9781119305101.ch11"},{"key":"3408_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801510","volume":"8","author":"MTC Mc Crudden","year":"2019","unstructured":"Mc Crudden MTC, Larra\u00f1eta E, Clark A, Jarrahian C, Rein-Weston A, Creelman B, et al. Design, formulation, and evaluation of novel dissolving microarray patches containing rilpivirine for intravaginal delivery. Adv Healthc Mater. 2019;8: e1801510.","journal-title":"Adv Healthc Mater"},{"key":"3408_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejpb.2019.09.011","volume":"144","author":"RKR Rajoli","year":"2019","unstructured":"Rajoli RKR, Flexner C, Chiong J, Owen A, Donnelly RF, Larra\u00f1eta E, Siccardi M. Modelling the intradermal delivery of microneedle array patches for long-acting a antiretrovirals using PBPK. Eur J Pharm Biopharm. 2019;144:101\u20139.","journal-title":"Eur J Pharm Biopharm"},{"key":"3408_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s13346-020-00848-8","volume":"11","author":"K Moffatt","year":"2020","unstructured":"Moffatt K, Quinn C, McCague PJ, Donnelly RF. Exploration into the opinions of patients with HIV, healthcare professionals and the lay public of the use of microneedles in clinical practice: highlighting the translational potential for their role in HIV infection. Drug Deliv Transl Res. 2020;11:1199\u2013217.","journal-title":"Drug Deliv Transl Res"},{"key":"3408_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jconrel.2018.11.002","volume":"292","author":"MTC Mc Crudden","year":"2018","unstructured":"Mc Crudden MTC, Larra\u00f1eta E, Clark A, Jarrahian C, Rein-Weston A, Lachau-Durand S, et al. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension. J Control Release. 2018;292:119\u201329.","journal-title":"J Control Release"},{"key":"3408_CR28","first-page":"129","volume":"71","author":"BP Sahu","year":"2014","unstructured":"Sahu BP, Das MK. Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide. Acta Pol Pharm. 2014;71:129\u201337.","journal-title":"Acta Pol Pharm"},{"key":"3408_CR29","first-page":"1","volume":"32","author":"IA Tekko","year":"2022","unstructured":"Tekko IA, Vora LK, Volpe-Zanutto F, Moffatt K, Jarrahian C, McCarthy HO, Donnelly RF. Novel bilayer microarray patch-assisted long-acting micro-depot cabotegravir intradermal delivery for HIV pre-exposure prophylaxis. Adv Funct Mater. 2022;32:1\u201318.","journal-title":"Adv Funct Mater"},{"key":"3408_CR30","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.carbpol.2017.11.018","volume":"181","author":"T Liua","year":"2018","unstructured":"Liua T, Hana M, Tianb F, Cuna D, Rantanenc J, Yang M. Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: in vitro and in vivo evaluation. Carbohydr Polym. 2018;181:1143\u201352.","journal-title":"Carbohydr Polym"},{"key":"3408_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jconrel.2017.07.032","volume":"265","author":"P Gonz\u00e1lez-V\u00e1zquez","year":"2017","unstructured":"Gonz\u00e1lez-V\u00e1zquez P, Larra\u00f1eta E, McCrudden MTC, Jarrahian C, Rein-Weston A, Quintanar-Solares M, Zehrung D, McCarthy H, Courtenay AJ, Donnelly RF. Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsis. J Control Release. 2017;265:30\u201340.","journal-title":"J Control Release"},{"key":"3408_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijpharm.2014.05.042","volume":"472","author":"E Larra\u00f1eta","year":"2014","unstructured":"Larra\u00f1eta E, Moore J, Vicente-P\u00e9rez EM, Gonz\u00e1lez-V\u00e1zquez P, Lutton R, Woolfson AD, Donnelly RF. A proposed model membrane and test method for microneedle insertion studies. Int J Pharm. 2014;472:65\u201373.","journal-title":"Int J Pharm"},{"key":"3408_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2019.10.004","volume":"316","author":"AD Permana","year":"2019","unstructured":"Permana AD, Tekko IA, McCrudden MTC, Anjani QK, Ramadon D, McCarthy HO, Donnelly RF. Solid lipid nanoparticle-based dissolving microneedles: a promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis. J Control Release. 2019;316:34\u201352.","journal-title":"J Control Release"},{"key":"3408_CR34","doi-asserted-by":"crossref","unstructured":"Smith GHR, Henry WK, Podzamczer D, Masi\u00e1 MDM, Bettacchi CJ, Arasteh K, et al. (2021). Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-Year Results From the LATTE-2 Study. Open Forum Infect Dis.8:ofab439.","DOI":"10.1093\/ofid\/ofab439"},{"key":"3408_CR35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel. Comput Methods Programs Biomed. 2010;99:306\u201314.","journal-title":"Comput Methods Programs Biomed"},{"key":"3408_CR36","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499\u2013510.","journal-title":"Lancet"},{"key":"3408_CR37","first-page":"157","volume":"8","author":"T Whitfield","year":"2016","unstructured":"Whitfield T, Torkington A, van Halsema C. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV AIDS. 2016;8:157\u201364.","journal-title":"HIV AIDS"},{"key":"3408_CR38","unstructured":"ICH Topic Q2 (R1) Validation of analytical procedures\u202f: Text and methodology (2005). http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf. Accessed 20 Jan 2022."},{"key":"3408_CR39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4314\/tjpr.v5i1.14634","volume":"5","author":"VJ Mohanraj","year":"2007","unstructured":"Mohanraj VJ, Chen Y. Nanoparticles - A review. Trop J Pharm Res. 2007;5:561\u201373.","journal-title":"Trop J Pharm Res"},{"key":"3408_CR40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/COH.0000000000000164","volume":"10","author":"PE Williams","year":"2015","unstructured":"Williams PE, Crauwels HM, Basstanie ED. Formulation and pharmacology of long-acting rilpivirine. Curr Opin HIV AIDS. 2015;10:233\u20138.","journal-title":"Curr Opin HIV AIDS"},{"key":"3408_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ijpharm.2008.11.029","volume":"370","author":"R Mauludin","year":"2009","unstructured":"Mauludin R, M\u00fcller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm. 2009;370:202\u20139.","journal-title":"Int J Pharm"},{"key":"3408_CR42","first-page":"42","volume":"01","author":"AJ Raval","year":"2011","unstructured":"Raval AJ, Patel MM. Preparation and characterization of nanoparticles for solubility and dissolution rate enhancement of meloxicam. Int Res J Pharm. 2011;01:42\u20139.","journal-title":"Int Res J Pharm"},{"key":"3408_CR43","first-page":"906","volume":"22","author":"L Lindfors","year":"2006","unstructured":"Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald Ripening Langmuir. 2006;22:906\u201310.","journal-title":"Inhibition of Ostwald Ripening Langmuir"},{"key":"3408_CR44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4103\/0975-7406.84459","volume":"3","author":"HP Thakkar","year":"2011","unstructured":"Thakkar HP, Patel BV, Thakkar SP. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. J Pharm Bioallied Sci. 2011;3:426\u201334.","journal-title":"J Pharm Bioallied Sci"},{"key":"3408_CR45","doi-asserted-by":"publisher","first-page":"12990","DOI":"10.1021\/la403077q","volume":"29","author":"BJ Larson","year":"2013","unstructured":"Larson BJ, Gillmor SD, Braun JM, Cruz-Barba LE, Savage DE, Denes FS, Lagally MG. Long-term reduction in Poly(dimethylsiloxane) surface hydrophobicity via cold-plasma treatments. Langmuir. 2013;29:12990\u20136.","journal-title":"Langmuir"},{"key":"3408_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11095-010-0169-8","volume":"28","author":"RF Donnelly","year":"2011","unstructured":"Donnelly RF, Majithiya R, Singh TRR, Morrow DIJ, Garland MJ, Demir YK, et al. Design, optimization and characterisation of polymeric microneedle arrays prepared by a novel laser-based micromoulding technique. Pharm Res. 2011;28:41\u201357.","journal-title":"Pharm Res"},{"key":"3408_CR47","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1128\/AAC.01529-09","volume":"54","author":"Van \u2019t Klooster G, Hoeben E, Borghy","year":"2010","unstructured":"Van \u2019t Klooster G, Hoeben E, Borghys H, Looszova A, Bouche MP, Van Velsen F, Baert L,. Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-acting Injectable Antiretroviral Formulation. Antimicrob Agents Chemother. 2010;54:2042\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"3408_CR48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2017.10.017","volume":"268","author":"BM Jucker","year":"2017","unstructured":"Jucker BM, Alsaid H, Rambo M, Lenhard SC, Hoang B, Xie F, et al. Multimodal imaging approach to examine biodistribution kknetics of cabotegravir (GSK1265744) long acting parenteral formulation in rat. J Control Release. 2017;268:102\u201312.","journal-title":"J Control Release"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03408-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-022-03408-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03408-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T05:06:53Z","timestamp":1691730413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-022-03408-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3408"],"URL":"https:\/\/doi.org\/10.1007\/s11095-022-03408-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"5 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ryan Donnelly is an inventor of patents that have been licenced to companies developing microarray patch-based products and is a paid advisor to a number of companies working towards commercialisation of this technology. The resulting potential conflict of interest has been disclosed and is managed by Queen\u2019s University Belfast. The companies had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results. No other author has any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}